.Attribute Medication, Released online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) procedure of clients along with HER2+ enhanced breast cancer cells and energetic or even stable mind metastases showed consistent intracranial task and wide spread efficacy of T-DXd.